北 京 大 成 （ 成 都 ） 律 师 事 务 所 关 于 四 川 千 里 倍 益 康 医 疗 科 技 股 份 有 限 公 司 2024 年年度 股 东 会 的 法律意见书 大成蓉（2025）法意字第 1019 号 北 京 大 成 （ 成 都 ） 律 师 事 务 所 www.dentons.cn 四川省成都市高新区天府二街吉瑞五路 396 号金控时代广场 2 栋 邮编：610000 Building 2 of Financial Holding Times Square, No. 396 Jirui 5th Road,Tianfu 2nd Stree,High-tech Zone,Chengdu,China Tel: +8628-87039931 Fax: +8628-87036893 北京大成（成都）律师事务所 关于四川千里倍益康医疗科技股份有限公司 2024 年年度股东会的法律意见书 致：四川千里倍益康医疗科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司股东会规则》《上市公司 治理准则》《北京证券交易所股票上市规则》等法 ...

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 291 million yuan, with a net profit attributable to shareholders of 27.78 million yuan, and total assets of 690 million yuan as of December 31, 2024 [4] - The company's revenue decreased by 12.78% year-on-year, with domestic revenue dropping by 38.27% and overseas revenue increasing by 45% [10] - The net cash flow from operating activities in 2024 was approximately 29.99 million yuan, a decrease of 47% compared to 2023 [8] Group 2: Investment and Assets - In 2024, the company added fixed assets primarily for production equipment and to solidify its upstream supply chain, enhancing production capacity and efficiency [4] - The company currently holds 19 medical device registration certificates covering various fields such as electrotherapy and oxygen therapy [5] Group 3: Product Development and Innovation - The company has made significant progress in new product development, with several products receiving regulatory approval, including the portable pneumatic massage system, which has also passed FDA 510(k) review [4] - Future product plans include the development of various rehabilitation devices, with a goal to launch 7-8 new products annually [9] Group 4: Strategic Goals for 2025 - The company aims to expand its market presence internationally and enhance its product offerings through innovation and brand building [5][6] - Key operational goals include optimizing production processes, improving product quality, and reducing production costs to enhance profitability [6] Group 5: Brand and Market Positioning - The company is focused on reducing reliance on a single product, with the muscle massager accounting for 89.72% of main business revenue [12] - Strategies to enhance brand competitiveness include increasing brand awareness through advertising and improving product quality through continuous R&D investment [13] Group 6: Cost Control Measures - The company has implemented advanced production equipment and automated production lines to improve efficiency and reduce unit production costs [14] - Supply chain management has been optimized to ensure timely supply and stable quality of raw materials, thereby reducing procurement costs [14]

证券代码：870199 证券简称：倍益康 公告编号：2025-043 四川千里倍益康医疗科技股份有限公司 关于持股 5%以上股东及其一致行动人 权益变动触及 1%的提示性公告 1 | 股东名称 | 变动方式 | 减持股数 | 减持比例 | | --- | --- | --- | --- | | 千里致远 | 集中竞价 | 413,464 | 0.61% | | 千里志达 | 集中竞价 | 116,445 | 0.17% | 四川千里倍益康医疗科技股份有限（以下简称"公司"）于 2025 年 5 月 7 日 收到员工持股平台成都市千里致远企业管理中心（有限合伙）（以下简称"千里致 远"）和成都市千里志达企业管理中心（有限合伙）（以下简称"千里志达"）出具 的《股份减持进展告知函》，上述股东于 2025 年 5 月 6 日至 2025 年 5 月 7 日通 过集中竞价累计减持公司股份 529,909 股。 （二）本次权益变动前后，信息披露义务人及其一致行动人拥有上市公司权 益的股份情况： | 股东名称 | 股份性质 | 本次变动前持有股份 | | 本次变动后持有股份 | | | --- | --- | --- | ...

Group 1 - The company currently holds 19 medical device registration certificates covering various fields such as electrotherapy, oxygen therapy, physical therapy, and thermal therapy [2] - In 2024, the company launched new products including a bio-stimulation feedback device and a portable deep muscle massager, which received "Chengdu Industrial Boutique" certification, and has opened overseas markets with a pressure massage system certified by the US FDA [2] - New products such as medium frequency therapy devices, shortwave therapy devices, interference electric therapy devices, and pelvic floor rehabilitation therapy devices have obtained medical device registration certificates by early 2025, accelerating the commercialization process of the medical segment [2] Group 2 - The company emphasizes research and innovation, having successfully launched several market-demand-driven new products since its listing, including a variable amplitude deep muscle massager that has become a market hit due to its portability and diverse features [3] - The portable pressure massage system has gained recognition for its wireless design and comprehensive functional upgrades, making it an ideal choice for home and outdoor activities, receiving global user approval at the recent trade fair [3] - The company plans to continue launching home rehabilitation products such as therapy and moxibustion robots, aiming to cover health needs throughout the entire lifecycle, with a goal of developing 7-8 new products annually to maintain its leading position in the rehabilitation equipment sector [3]

Market Overview - On May 6, the Shanghai Composite Index rose by 1.13%, with the total margin financing balance reaching 1,801.34 billion yuan, an increase of 14.86 billion yuan from the previous trading day [1] - The margin financing balance in the Shanghai market was 916.02 billion yuan, up by 6.24 billion yuan; in the Shenzhen market, it was 880.20 billion yuan, up by 8.53 billion yuan; and in the Beijing Stock Exchange, it was 5.12 billion yuan, up by 0.09 billion yuan [1] Industry Analysis - Among the industries classified by Shenwan, 28 industries saw an increase in financing balance, with the electronics industry leading with an increase of 3.16 billion yuan, followed by the computer and machinery equipment industries with increases of 2.12 billion yuan and 1.27 billion yuan, respectively [1] Individual Stock Performance - A total of 2,239 stocks experienced an increase in financing balance, accounting for 61.01% of the total, with 480 stocks seeing an increase of over 5% [1] - The stock with the largest increase in financing balance was Beiyikang, with a latest financing balance of 12.05 million yuan, reflecting an increase of 85.23% from the previous trading day; its stock price rose by 13.94% [1] - Other notable stocks with significant increases in financing balance included Guangda Tongchuang and Haineng Technology, with increases of 72.55% and 66.50%, respectively [1][2] Top Gainers and Losers - Among the top 20 stocks with the largest increase in financing balance, the average increase in stock price was 5.73%, with notable gainers including Jiuling Technology, Beiyikang, and Qushui Technology, which rose by 29.99%, 13.94%, and 10.28%, respectively [2] - Conversely, 1,430 stocks saw a decrease in financing balance, with 152 stocks experiencing a decline of over 5%; the stock with the largest decrease was Lijing Navigation, with a financing balance of 5.41 million yuan, down by 79.84% [4][5]

成交方面，全天成交额超亿元的股票共有91只，成交额居前的北交所股票有并行科技、开发科技、艾融 软件等，成交额分别为9.20亿元、5.30亿元、4.57亿元。 股票活跃度来看，今日可交易的北交所个股中，换手率超10%的有62只，其中，14股换手率超20%，换 手率在5%~10%之间的有101只，换手率在1%~5%之间的有98只。全天换手率居前的股票有*ST广道、 春光智能、倍益康等，换手率分别为34.66%、33.92%、32.53%。（数据宝） 证券时报·数据宝统计显示，今日可交易北交所个股中，收盘股价上涨的有260只，占可交易个股的 98.11%，收盘涨停的有慧为智能、九菱科技等，收盘涨幅居前的有卓兆点胶、惠同新材、众诚科技， 分别上涨19.85%、19.28%、18.24%。收盘股价下跌的有5只，跌幅居前的有*ST广道、*ST云创、诺思 兰德等，分别下跌23.60%、9.23%、2.79%。 | 代码 | 简称 | 收盘价（元） | 涨跌幅（%） | 换手率（%） | 成交额（万元） | | --- | --- | --- | --- | --- | --- | | 839493 | 并行科技 | 180 ...

一、股票交易异常波动的具体情况 公司股票最近 2 个有成交的交易日（2025 年 4 月 30 日至 2025 年 5 月 6 日）以内收盘 价涨幅偏离值累计达到 41.81%，根据《北京证券交易所交易规则（试行）》的有关规定，属 于股票交易异常波动情形。 二、公司关注并核实的相关情况 1、 核实对象： 公司控股股东、实际控制人及一致行动人，持股 5%以上股东，在任的董事、监事及高 级管理人员。 2、 核实方式： 电话询问、口头询问、微信询问等方式。 证券代码：870199 证券简称:倍益康 公告编号：2025-042 四川千里倍益康医疗科技股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 三、是否存在应披露而未披露的重大信息的声明 本公司董事会确认，本公司没有任何根据《北京证券交易所股票上市规则》等有关规定 应披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等，董事会也未获悉本公 司有根据《北京证券交易所股票上市规则》等有关规定应披露而未披露的、对本公司股票交 易 ...

倍益康（870199）今日涨停，全天换手率23.38%，成交额2.36亿元，振幅26.53%。龙虎榜数据显示，营 业部席位合计净买入565.93万元。 倍益康4月30日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 东莞证券股份有限公司厦门分公司 | 875.70 | 0.00 | | 买二 | 上海证券有限责任公司宁波北仑新大路证券营业部 | 599.69 | 0.00 | | 买三 | 中国中金财富证券有限公司广州分公司 | 478.77 | 36.01 | | 买四 | 中信证券股份有限公司杭州文三路证券营业部 | 467.81 | 3.46 | | 买五 | 中信建投证券股份有限公司合肥创新大道证券营业部 | 444.69 | 0.00 | | 卖一 | 国信证券股份有限公司深圳互联网分公司 | 118.89 | 1044.99 | | 卖二 | 广发证券股份有限公司沈阳小西路营业部 | 0.00 | 655.91 | | 卖三 | 东方财富证券股份有限公司拉萨团结路第二证券营业 部 | ...

- The provided content does not include any quantitative models or factors, nor their construction methods, formulas, evaluations, or backtesting results[1][2][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]

证券代码：870199 证券简称：倍益康 公告编号：2025-041 四川千里倍益康医疗科技股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 四川千里倍益康医疗科技股份有限公司（以下简称"公司"）于 2025 年 4月18日在北京证券交易所官方信息披露平台（http://www.bse.cn）发布了《2024 年年度报告》（公告编号：2025-016），为方便广大投资者更深入了解公司 2024 年年度经营业绩的具体情况，公司拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 7 日 15:00-17:00。 （二）会议召开地点 本次年报业绩说明会将采用网络远程的方式举行，投资者可登陆全景网 "投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 三、 参加人员 公司董事长、总经理：张文 先生 本次说明会采用网络方式召开。 为充分尊重投资者、提 ...